Currently out of the existing stock ratings of Chalres Zhu, 405 are a BUY (77.14%), 115 are a HOLD (21.9%), 5 are a SELL (0.95%).

Chalres Zhu

Work Performance Price Targets & Ratings Chart

Analyst Chalres Zhu, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 22.22% that have a potential upside of 9.64% achieved within 44 days.

Chalres Zhu’s has documented 38 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MGNX, MacroGenics at 23-Nov-2022.

Wall Street Analyst Chalres Zhu

Analyst best performing recommendations are on ZYME (ZYMEWORKS . COMMON STOCK).
The best stock recommendation documented was for ZYME (ZYMEWORKS . COMMON STOCK) at 11/20/2019. The price target of $48 was fulfilled within 58 days with a profit of $9.24 (23.84%) receiving and performance score of 4.11.

Average potential price target upside

RPTX Repare Therapeutics XNCR Xencor IDYA Ideaya Biosciences MGNX MacroGenics MRUS Merus BV ZYME Zymeworks . Common Stock

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$10

$6.89 (221.54%)

$10

13 days ago
(08-Nov-2024)

0/17 (0%)

$6.42 (179.33%)

Buy

$25

$21.89 (703.86%)

$30

1 years 1 months 5 days ago
(16-Oct-2023)

2/6 (33.33%)

$19.91 (391.16%)

141

Buy

$17

$13.89 (446.62%)

$16

1 years 1 months 27 days ago
(25-Sep-2023)

1/5 (20%)

$4.3 (33.86%)

6

Buy

$28

$24.89 (800.32%)

$43

1 years 6 months 11 days ago
(10-May-2023)

0/2 (0%)

$17.42 (164.65%)

$14

$10.89 (350.16%)

$15

1 years 8 months 25 days ago
(27-Feb-2023)

1/5 (20%)

$3.45 (32.70%)

147

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Chalres Zhu?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?